Company: REVB
Filing Date: 2025-05-23
Form Type: S-1/A
Source: 0001213900-25-047104
Chunk: 218

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-23
Form: S-1/A
Chunk 218
---
254 | ) |

| (1) | Other program expenses include pre-clinical costs and clinical 
 preparation costs primarily for our Product Candidates.        |

| (2) | Other research and development expenses primarily consist                                                                    
 of facilities charges, third party consultant costs, costs related to other product candidates, and other unallocated costs. |

| (3) | LifeSci Capital LLC judgment expense, reimbursement of costs,                                                                                  
 clinical trial related settlement expenses with A-IR Clinical Research Ltd., expense in connection with the deferred underwriting commissions, 
 foreign currency transaction gains and losses and interest income from our cash balances in savings accounts.                                  |

13. Subsequent Event 2021 Equity Plan Stock Increase On January 1, 2025, the number of shares of common stock available under the 2021 Plan increased to 156,512as per the Evergreen Feature in the 2021 Plan. Restricted Stock Awards Granted On February 11, 2025, 58,568Restricted Stock Awards, were granted to employees and the Board of Directors which resulted in a fair value of $ 0.2million of stock-based compensation expense based on the Company’s stock price on the date of grant. The grants were granted from shares of the 2021 Plan and either vest 100% on the date of grant or vest 50% on the date of grant, with 50% vesting on the vest oneyear thereafter. Regaining Nasdaq Compliance As previously reported on October 16, 2024, the Company received a letter from Nasdaq notifying the Company of its noncompliance with Nasdaq Listing Rule 5550(a)(2) by failing to maintain a minimum bid price for its common stock of at least $ 1.00per share for 30consecutive business days. The Company had until February 14, 2025, to regain compliance by having a minimum closing bid price of at least $ 1.00per share for at least 10consecutive business days. On February 19, 2025 the Company received a formal notice from Nasdaq stating that the Company’s common stock will continue to be listed and traded on Nasdaq, due to the Company having regained compliance with the minimum bid price requirement, and all applicable listing standards. Class F Common Stock Warrant Exercises As of March 3, 2025, the Company received alternative cashless exercise notices for 3,064,040Class F Common Stock Warrants to purchase 383,006shares of common stock issued